LNTH Lantheus Holdings Inc

Lantheus to Present at Upcoming Investor Conferences

Lantheus to Present at Upcoming Investor Conferences

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences.

  • B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28
  • TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ET
  • Leerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET

A live webcast will be available for the TD Cowen 45th Annual Health Care Conference and Leerink Global Healthcare Conference presentations on the Investors section of the Company’s website at . A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentations.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

Melissa Downs

Senior Director, External Communications

646-975-2533



EN
21/02/2025

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at Upcoming Investor Conferences

Lantheus to Present at Upcoming Investor Conferences BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ETLeerink Global Hea...

February 21, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference...

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the sch...

February 12, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 1...

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced pifl...

February 5, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Membe...

Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical deve...

January 30, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $25...

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVY™, a registrational-stage diagnostic asset, targeting neuroendocrine tumors that is complementary to Lantheus’ therapeutic agent, PNT2003 Expands oncology radiopharmaceutical pipeline with multiple clinical and pre-clinical theranostic pairs Company reaffirms Full-Year and Fourth ...

January 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch